TriangleNCT02301039 · OUTCOME
Adverse Events Related to Pembrolizumab Treatment in Patients With Advanced Sarcoma, by Patient
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Grade 3 or higher treatment related AEs
- Interval / dispersion
- Not reported
- Time frame
- Up to 5 years
What was measured
Related Adverse Event is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a investigational product and related to the investigational product.
Groups in this outcome
Soft Tissue Sarcoma
Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab was administered at 200 mg intravenously every 3 weeks Pembrolizumab
Bone Sarcoma
Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \[de-differentiated or mesenchymal\]. Pembrolizumab was administered at 200 mg intravenously every 3 weeks Pembrolizumab
Expansion Cohort
Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
| Group | Source count |
|---|---|
| Soft Tissue Sarcoma | 42 |
| Bone Sarcoma | 42 |
| Expansion Cohort | 60 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Soft Tissue Sarcoma | 6 | Not reported | Not reported | Not reported | Not reported |
| Bone Sarcoma | 9 | Not reported | Not reported | Not reported | Not reported |
| Expansion Cohort | 10 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 9
- group Id
- OG002
- value
- 10
- denoms
- counts
- group Id
- OG000
- value
- 42
- group Id
- OG001
- value
- 42
- group Id
- OG002
- value
- 60
- units
- Participants
- description
- Related Adverse Event is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a investigational product and related to the investigational product.
- groups
- description
- Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab was administered at 200 mg intravenously every 3 weeks Pembrolizumab
- id
- OG000
- title
- Soft Tissue Sarcoma
- description
- Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \[de-differentiated or mesenchymal\]. Pembrolizumab was administered at 200 mg intravenously every 3 weeks Pembrolizumab
- id
- OG001
- title
- Bone Sarcoma
- description
- Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
- id
- OG002
- title
- Expansion Cohort
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Adverse Events Related to Pembrolizumab Treatment in Patients With Advanced Sarcoma, by Patient
- type
- SECONDARY
- unit Of Measure
- Grade 3 or higher treatment related AEs
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice